Despite the fact that research works have reported both positive and negative results, several genetic variants in identified IBD genes (TLR4, MDR1, and CRP) may predict the efficiency of anti‐TNFα biological drugs [48]. This evidence concerns the gene CRP and inflammatory bowel disease.